Bethany Sleckman

1.5k total citations
19 papers, 505 citations indexed

About

Bethany Sleckman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bethany Sleckman has authored 19 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Bethany Sleckman's work include Advanced Breast Cancer Therapies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Bethany Sleckman is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Bethany Sleckman collaborates with scholars based in United States, Canada and Australia. Bethany Sleckman's co-authors include Ramaswamy Govindan, Naiyer A. Rizvi, David Bodkin, Malcolm Ranson, Paul Germonpré, Paul K. Stockman, Ronald B. Natale, Sarah J. Kennedy, Wilfried Eberhardt and Walter M. Stadler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Bethany Sleckman

19 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bethany Sleckman United States	10	365	270	201	99	72	19	505
Johann Raats South Africa	9	367 1.0×	280 1.0×	188 0.9×	101 1.0×	83 1.2×	15	569
Claudia-Nanette Gann Germany	4	479 1.3×	537 2.0×	227 1.1×	60 0.6×	116 1.6×	9	767
Hielke J. Meulenbeld Netherlands	11	283 0.8×	316 1.2×	149 0.7×	89 0.9×	176 2.4×	17	577
Daniel P. Petro United States	11	243 0.7×	194 0.7×	188 0.9×	40 0.4×	49 0.7×	21	428
Samuel Suzuki United States	9	228 0.6×	130 0.5×	214 1.1×	65 0.7×	102 1.4×	22	460
Martina Makrutzki Spain	8	500 1.4×	285 1.1×	268 1.3×	128 1.3×	105 1.5×	14	699
Herb Kotz United States	11	325 0.9×	130 0.5×	148 0.7×	39 0.4×	86 1.2×	23	494
Eugene Paschold United States	8	428 1.2×	347 1.3×	154 0.8×	39 0.4×	83 1.2×	12	592
Yoojoo Lim South Korea	14	201 0.6×	117 0.4×	162 0.8×	83 0.8×	127 1.8×	56	485
Karen Giselle Chee United States	7	182 0.5×	163 0.6×	102 0.5×	69 0.7×	36 0.5×	9	380

Countries citing papers authored by Bethany Sleckman

Since Specialization

Citations

This map shows the geographic impact of Bethany Sleckman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bethany Sleckman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bethany Sleckman more than expected).

Fields of papers citing papers by Bethany Sleckman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bethany Sleckman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bethany Sleckman. The network helps show where Bethany Sleckman may publish in the future.

Co-authorship network of co-authors of Bethany Sleckman

This figure shows the co-authorship network connecting the top 25 collaborators of Bethany Sleckman. A scholar is included among the top collaborators of Bethany Sleckman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bethany Sleckman. Bethany Sleckman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Rugo, Hope S., Seock‐Ah Im, Anil A. Joy, et al.. (2023). The Effects of Adding Palbociclib to Endocrine Therapy to Treat Advanced Breast Cancer: A Plain Language Summary of a Study Using the PALOMA-2 and PALOMA-3 Trial Results. Future Oncology. 20(1). 5–16. 2 indexed citations

Tripathy, Debu, Joanne L. Blum, Bethany Sleckman, et al.. (2023). Abstract P3-01-03: Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS. Cancer Research. 83(5_Supplement). P3–1. 1 indexed citations

Rugo, Hope S., Seock‐Ah Im, Anil A. Joy, et al.. (2022). Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. The Breast. 66. 324–331. 3 indexed citations

Isaacs, Claudine, Reshma Mahtani, Filipa Lynce, et al.. (2022). Abstract P1-18-13: Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials. Cancer Research. 82(4_Supplement). P1–18. 1 indexed citations

Major, Ajay, Justin Kline, Theodore Karrison, et al.. (2021). Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 107(7). 1608–1618. 21 indexed citations

Seiwert, Tanguy Y., Sara Kochanny, Kevin Wood, et al.. (2020). A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Cancer. 126(14). 3237–3243. 15 indexed citations

Carlson, Jay W., Jiajing Chen, Michelle M. Smith, et al.. (2020). An analysis of inpatient and ED admissions within 30 days of chemotherapy: An OP-35 review.. Journal of Clinical Oncology. 38(15_suppl). e19302–e19302. 1 indexed citations

Major, Ajay, Justin Kline, Theodore Karrison, et al.. (2020). Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. Blood. 136(Supplement 1). 43–44. 3 indexed citations

Gelmon, Karen A., Massimo Cristofanilli, Hope S. Rugo, et al.. (2019). Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer. The Breast Journal. 26(3). 368–375. 10 indexed citations

10.

Rocque, Gabrielle B., Joanne L. Blum, Aldemar Montero, et al.. (2019). Understanding palbociclib practice patterns in a real-world setting.. Journal of Clinical Oncology. 37(27_suppl). 200–200. 1 indexed citations

11.

Kline, Justin, Aaron P. Rapoport, Adam M. Petrich, et al.. (2016). Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309. Blood. 128(22). 4147–4147. 2 indexed citations

12.

Catenacci, Daniel Virgil Thomas, Nathan Bahary, Sreenivasa Nattam, et al.. (2013). Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.. Journal of Clinical Oncology. 31(15_suppl). 4012–4012. 31 indexed citations

13.

Catenacci, Daniel Virgil Thomas, Nathan Bahary, Martin J. Edelman, et al.. (2012). A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.. Journal of Clinical Oncology. 30(15_suppl). 4022–4022. 17 indexed citations

14.

Sharma, Manish, Kristen Wroblewski, Blasé N. Polite, et al.. (2011). Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 30(3). 1211–1215. 43 indexed citations

15.

Sharma, Monica, Kristen Wroblewski, Mark Kozloff, et al.. (2011). Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium.. Journal of Clinical Oncology. 29(4_suppl). 506–506. 3 indexed citations

16.

Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations

17.

Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2006). ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Journal of Clinical Oncology. 24(18_suppl). 7000–7000. 85 indexed citations

18.

Bodkin, David, Ramaswamy Govindan, Bethany Sleckman, et al.. (2005). O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study. Lung Cancer. 49. S37–S37. 28 indexed citations

19.

Sleckman, Bethany, Peter Mauch, Richard F. Ambinder, et al.. (1998). Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection.. PubMed. 7(12). 1117–21. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact